| Literature DB >> 35922824 |
Rongyang Li1, Mengchao Xue1, Zheng Ma1, Chenghao Qu1, Kun Wang1, Yu Zhang1, Weiming Yue1, Huiying Zhang1, Hui Tian2.
Abstract
BACKGROUND: Prolonged air leak (PAL) remains one of the most frequent postoperative complications after pulmonary resection. This study aimed to develop a predictive nomogram to estimate the risk of PAL for individual patients after minimally invasive pulmonary resection.Entities:
Keywords: Minimally invasive pulmonary resection; Nomogram; Predictive model; Prolonged air leak; Risk factor
Mesh:
Year: 2022 PMID: 35922824 PMCID: PMC9347096 DOI: 10.1186/s12957-022-02716-w
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 3.253
Fig. 1Flow diagram of patient selection through the study. PAL, prolonged air leak
Patients’ characteristics of the training cohort and validation cohort
| Characteristics | All cohort | Training cohort | Validation cohort | |
|---|---|---|---|---|
| Age (years), median (IQR) | 58.00 (51.00–66.00) | 58.00 (51.00–66.00) | 58.00 (52.00–66.00) | 0.607 |
| Gender, | 0.353 | |||
| Female | 1274 (57.6) | 965 (58.1) | 309 (55.9) | |
| Male | 939 (42.4) | 695 (41.9) | 244 (44.1) | |
| BMI (kg/m2), median (IQR) | 24.77 (22.77–27.01) | 24.71 (22.77–26.95) | 25.04 (22.83–27.26) | 0.153 |
| Smoking history, | 0.314 | |||
| Non-smoker | 1625 (73.4) | 1228 (74.0) | 397 (71.8) | |
| Smoker | 588 (26.6) | 432 (26.0) | 156 (28.2) | |
| Hypertension, | 0.248 | |||
| No | 1591 (71.9) | 1204 (72.5) | 387 (70.0) | |
| Yes | 622 (28.1) | 456 (27.5) | 166 (30.0) | |
| Diabetes mellitus, | 0.156 | |||
| No | 1926 (87.0) | 1435 (86.4) | 491 (88.8) | |
| Yes | 287 (13.0) | 225 (13.6) | 62 (11.2) | |
| COPD, | 0.804 | |||
| No | 2191 (99.0) | 1644 (99.0) | 547 (98.9) | |
| Yes | 22 (1.0) | 16 (1.0) | 6 (1.1) | |
| Neoadjuvant therapy, | 0.640 | |||
| No | 2174 (98.2) | 1632 (98.3) | 542 (98.0) | |
| Yes | 39 (1.8) | 28 (1.7) | 11 (2.0) | |
| History of thoracic surgery, | 0.255 | |||
| No | 2187 (98.8) | 1638 (98.7) | 549 (99.3) | |
| Yes | 26 (1.2) | 22 (1.3) | 4 (0.7) | |
| FEV1 % predicted (%), median (IQR) | 104.46 (93.35–115.58) | 104.55 (92.89–115.71) | 104.35 (94.63–115.11) | 0.674 |
| MVV % predicted (%), median (IQR) | 103.15 (90.24–115.63) | 102.74 (89.91–115.46) | 104.82 (91.18–116.26) | 0.201 |
| Blood type, | 0.670 | |||
| A | 637 (28.8) | 479 (28.9) | 158 (28.6) | |
| B | 763 (34.5) | 578 (34.8) | 185 (33.5) | |
| AB | 230 (10.4) | 165 (9.9) | 65 (11.8) | |
| O | 583 (26.3) | 438 (26.4) | 145 (26.2) | |
| Lymphocyte (×109/L), median (IQR) | 1.78 (1.46–2.18) | 1.79 (1.45–2.18) | 1.77 (1.49–2.16) | 0.791 |
| Albumin (g/L), median (IQR) | 59.70 (57.60–61.90) | 59.80 (57.60–61.90) | 59.70 (57.50–61.90) | 0.635 |
| PNI (%), median (IQR) | 68.95 (66.05–71.65) | 68.95 (66.05–71.60) | 68.90 (65.85–71.98) | 0.839 |
| ASA score, | 0.185 | |||
| I | 212 (9.6) | 162 (9.8) | 50 (9.0) | |
| II | 1934 (87.4) | 1454 (87.6) | 480 (86.8) | |
| III | 67 (3.0) | 44 (2.7) | 23 (4.2) | |
| Surgical technique, | 0.200 | |||
| RATS | 743 (33.6) | 545 (32.8) | 198 (35.8) | |
| VATS | 1470 (66.4) | 1115 (67.2) | 355 (64.2) | |
| Surgical procedure, | 0.932 | |||
| Sublobar resection | 1041 (47.0) | 780 (47.0) | 261 (47.2) | |
| Lobectomy | 1172 (53.0) | 880 (53.0) | 292 (52.8) | |
| Surgical range, | 0.256 | |||
| Mono-lobe | 1909 (86.3) | 1424 (85.8) | 485 (87.7) | |
| Multi-lobe | 304 (13.7) | 236 (14.2) | 68 (12.3) | |
| Operation side, | 0.972 | |||
| Left-sided | 875 (39.5) | 656 (39.5) | 219 (39.6) | |
| Right-sided | 1338 (60.5) | 1004 (60.5) | 334 (60.4) | |
| Operation duration (min), median (IQR) | 90.00 (70.00–120.00) | 90.00 (70.00–120.00) | 90.00 (70.00–115.00) | 0.181 |
| Number of LNs dissected, median (IQR) | 6.00 (4.00–10.00) | 6.00 (4.00–10.00) | 6.00 (4.00–10.00) | 0.941 |
| Tumor size (cm), median (IQR) | 1.40 (1.00–2.00) | 1.40 (1.00–2.00) | 1.50 (1.00–2.00) | 0.885 |
| Prolonged air leak | 0.662 | |||
| No | 1872 (84.6) | 1401 (84.4) | 471 (85.2) | |
| Yes | 341 (15.4) | 259 (15.6) | 82 (14.8) |
IQR interquartile range, BMI body mass index, COPD chronic obstructive pulmonary diseases, FEV1 forced expiratory volume in one second, MVV maximal voluntary ventilation, PNI prognostic nutritional index, ASA American Society of Anesthesiologists, RATS robotic-assisted thoracic surgery, VATS video-assisted thoracic surgery, LN lymph node
† P-value for the comparison between training cohort and validation cohort
Clinical characteristics of patients with or without PAL in training cohort and validation cohort
| Characteristics | Training cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
| Non-PAL | PAL | Non-PAL | PAL | |||
| Age (years), median (IQR) | 58.0 (51.0–65.0) | 62.0 (54.0–69.0) | <0.001 | 57.0 (51.0–65.0) | 63.0 (55.5–69.0) | 0.002 |
| Gender, | <0.001 | <0.001 | ||||
| Female | 842 (60.1) | 123 (47.5) | 284 (60.3) | 25 (30.5) | ||
| Male | 559 (39.9) | 136 (52.5) | 187 (39.7) | 57 (69.5) | ||
| BMI (kg/m2), median (IQR) | 24.9 (22.9–27.1) | 24.0 (22.1–26.0) | <0.001 | 25.3 (23.0–27.3) | 24.1 (22.3–26.6) | 0.052 |
| Smoking history, | <0.001 | 0.009 | ||||
| Non-smoker | 1074 (76.7) | 154 (59.5) | 348 (73.9) | 49 (59.8) | ||
| Smoker | 327 (23.3) | 105 (40.5) | 123 (26.1) | 33 (40.2) | ||
| Hypertension, | 0.299 | 0.872 | ||||
| No | 1023 (73.0) | 181 (69.9) | 329 (69.9) | 58 (70.7) | ||
| Yes | 378 (27.0) | 78 (30.1) | 142 (30.1) | 24 (29.3) | ||
| Diabetes mellitus, | 0.983 | 0.760 | ||||
| No | 1211 (86.4) | 224 (86.5) | 419 (89.0) | 72 (87.8) | ||
| Yes | 190 (13.6) | 35 (13.5) | 52 (11.0) | 10 (12.2) | ||
| COPD, | 0.028 | 0.219 | ||||
| No | 1391 (99.3) | 253 (97.7) | 467 (99.2) | 80 (97.6) | ||
| Yes | 10 (0.7) | 6 (2.3) | 4 (0.8) | 2 (2.4) | ||
| Neoadjuvant therapy, | 0.066 | 0.383 | ||||
| No | 1381 (98.6) | 251 (96.9) | 460 (97.7) | 82 (100.0) | ||
| Yes | 20 (1.4) | 8 (3.1) | 11 (2.3) | 0 | ||
| History of thoracic surgery, | 0.560 | 0.107 | ||||
| No | 1381 (98.6) | 257 (99.2) | 469 (99.6) | 80 (97.6) | ||
| Yes | 20 (1.4) | 2 (0.8) | 2 (0.4) | 2 (2.4) | ||
| FEV1 % predicted (%), median (IQR) | 105.3 (93.9–116.0) | 100.5 (87.1–113.2) | <0.001 | 105.3 (95.4–115.8) | 99.2 (86.9–111.4) | <0.001 |
| MVV % predicted (%), median (IQR) | 103.2 (91.1–116.0) | 98.2 (85.1–112.1) | <0.001 | 104.9 (92.5–117.1) | 95.2 (85.7–107.3) | <0.001 |
| Blood type, | 0.188 | 0.199 | ||||
| A | 396 (28.3) | 83 (32.0) | 140 (29.7) | 18 (22.0) | ||
| B | 490 (35.0) | 88 (34.0) | 151 (32.1) | 34 (41.5) | ||
| AB | 148 (10.6) | 17 (6.6) | 53 (11.3) | 12 (14.6) | ||
| O | 367 (26.2) | 71 (27.4) | 127 (27.0) | 18 (22.0) | ||
| Lymphocyte (×109/L), median (IQR) | 1.79 (1.46–2.20) | 1.73 (1.41–2.13) | 0.075 | 1.78 (1.49–2.16) | 1.68 (1.43–2.20) | 0.306 |
| Albumin (g/L), median (IQR) | 59.8 (57.6–61.9) | 59.9 (57.6–62.2) | 0.395 | 59.7 (57.4–61.9) | 60.1 (57.7–62.1) | 0.765 |
| PNI (%), median (IQR) | 69.0 (66.1–71.6) | 68.8 (65.8–72.0) | 0.992 | 69.0 (66.0–72.0) | 68.8 (65.0–72.1) | 0.840 |
| ASA score, | 0.005 | 0.355 | ||||
| I | 143 (10.2) | 19 (7.3) | 46 (9.8) | 4 (4.9) | ||
| II | 1228 (87.7) | 226 (87.3) | 406 (86.2) | 74 (90.2) | ||
| III | 30 (2.1) | 14 (5.4) | 19 (4.0) | 4 (4.9) | ||
| Surgical technique, | 0.316 | 0.066 | ||||
| RATS | 453 (32.3) | 92 (35.5) | 176 (37.4) | 22 (26.8) | ||
| VATS | 948 (67.7) | 167 (64.5) | 295 (62.6) | 60 (73.2) | ||
| Surgical procedure, | <0.001 | <0.001 | ||||
| Sublobar resection | 712 (50.8) | 68 (26.3) | 239 (50.7) | 22 (26.8) | ||
| Lobectomy | 689 (49.2) | 191 (73.7) | 232 (49.3) | 60 (73.2) | ||
| Surgical range, | 0.001 | 0.288 | ||||
| Mono-lobe | 1219 (87.0) | 205 (79.2) | 416 (88.3) | 69 (84.1) | ||
| Multi-lobe | 182 (13.0) | 54 (20.8) | 55 (11.7) | 13 (15.9) | ||
| Operation side, | 0.141 | 0.388 | ||||
| Left-sided | 543 (38.8) | 113 (43.6) | 183 (38.9) | 36 (43.9) | ||
| Right-sided | 858 (61.2) | 146 (56.4) | 288 (61.1) | 46 (56.1) | ||
| Operation duration (min), median (IQR) | 90.0 (70.0–115.0) | 110 (85.0–140.0) | <0.001 | 90.0 (70.0–110.0) | 107.5 (80.0–125.0) | <0.001 |
| Number of LNs dissected, median (IQR) | 6.0 (4.0–9.0) | 8.0 (5.0–12.0) | <0.001 | 6.0 (4.0–9.0) | 7.5 (5.0–12.3) | 0.001 |
| Tumor size (cm), median (IQR) | 1.3 (0.9–2.0) | 1.5 (1.2–2.5) | <0.001 | 1.3 (0.9–2.0) | 2.0 (1.5–3.0) | <0.001 |
PAL prolonged air leak, IQR interquartile range, BMI body mass index, COPD chronic obstructive pulmonary diseases, FEV1 forced expiratory volume in one second, MVV maximal voluntary ventilation, PNI prognostic nutritional index, ASA American Society of Anesthesiologists, RATS robotic-assisted thoracic surgery, VATS video-assisted thoracic surgery, LN lymph node
Univariate and multivariate logistic regression analysis of risk factors for PAL in the training cohort
| Variables | PAL rate (%) | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | ||||
| Age | 15.6 | 1.029 | 1.016–1.043 | < 0.001 | 1.020 | 1.004–1.037 | 0.013 |
| Gender | < 0.001 | 0.819 | |||||
| Female | 12.7 | Ref. | Ref. | ||||
| Male | 19.6 | 1.665 | 1.276–2.174 | 0.951 | 0.619–1.462 | ||
| BMI | 15.6 | 0.914 | 0.875–0.955 | < 0.001 | 0.884 | 0.842–0.928 | < 0.001 |
| Smoking history | < 0.001 | 0.030 | |||||
| Non-smoker | 12.5 | Ref. | Ref. | ||||
| Smoker | 24.3 | 2.239 | 1.697–2.955 | 1.628 | 1.048–2.531 | ||
| Hypertension | 0.299 | ||||||
| No | 15.0 | Ref. | |||||
| Yes | 17.1 | 1.166 | 0.872–1.559 | ||||
| Diabetes mellitus | 0.996 | ||||||
| No | 15.6 | Ref. | |||||
| Yes | 15.6 | 0.996 | 0.676–1.467 | ||||
| COPD | 0.022 | 0.080 | |||||
| No | 15.4 | Ref. | Ref. | ||||
| Yes | 37.5 | 3.299 | 1.188–9.157 | 2.836 | 0.883–9.107 | ||
| Neoadjuvant therapy | 0.063 | 0.753 | |||||
| No | 15.4 | Ref. | Ref. | ||||
| Yes | 28.6 | 2.201 | 0.959–5.052 | 0.862 | 0.343–2.165 | ||
| History of thoracic surgery | 0.404 | ||||||
| No | 15.7 | Ref. | |||||
| Yes | 9.1 | 0.537 | 0.125–2.313 | ||||
| FEV1 % predicted | 15.6 | 0.983 | 0.976–0.991 | < 0.001 | 0.991 | 0.981–1.000 | 0.046 |
| MVV% predicted | 15.6 | 0.989 | 0.983–0.996 | 0.002 | 0.999 | 0.994–1.004 | 0.639 |
| Blood type | 0.195 | 0.166 | |||||
| A | 17.3 | Ref. | Ref. | ||||
| B | 15.2 | 0.857 | 0.617–1.189 | 0.877 | 0.618–1.244 | ||
| AB | 10.3 | 0.548 | 0.315–0.955 | 0.509 | 0.282–0.919 | ||
| O | 16.2 | 0.923 | 0.652–1.306 | 0.912 | 0.627–1.326 | ||
| Lymphocyte | 15.6 | 0.804 | 0.631–1.023 | 0.076 | 0.902 | 0.697–1.168 | 0.433 |
| Albumin | 15.6 | 1.015 | 0.986–1.046 | 0.313 | |||
| PNI | 15.6 | 0.999 | 0.975–1.024 | 0.955 | |||
| ASA score | 0.007 | 0.264 | |||||
| I | 11.7 | Ref. | Ref. | ||||
| II | 15.5 | 1.385 | 0.841–2.282 | 0.879 | 0.497–1.555 | ||
| III | 31.8 | 3.512 | 1.587–7.775 | 1.590 | 0.622–4.063 | ||
| Surgical technique | 0.316 | ||||||
| RATS | 16.9 | Ref. | |||||
| VATS | 15.0 | 0.867 | 0.657–1.145 | ||||
| Surgical procedure | < 0.001 | < 0.001 | |||||
| Sublobar resection | 8.7 | Ref. | Ref. | ||||
| Lobectomy | 21.7 | 2.903 | 2.159–3.902 | 2.100 | 1.424–3.096 | ||
| Surgical range | 0.001 | 0.002 | |||||
| Mono-lobe | 14.4 | Ref. | Ref. | ||||
| Multi-lobe | 22.9 | 1.764 | 1.258–2.473 | 1.820 | 1.251–2.648 | ||
| Operation side | 0.141 | 0.035 | |||||
| Left-sided | 17.2 | Ref. | Ref. | ||||
| Right-sided | 14.5 | 0.818 | 0.625–1.069 | 0.730 | 0.545–0.977 | ||
| Operation duration | 15.6 | 1.012 | 1.009–1.016 | < 0.001 | 1.009 | 1.005–1.012 | < 0.001 |
| Number of LN dissected | 15.6 | 1.076 | 1.051–1.102 | < 0.001 | 1.019 | 0.989–1.050 | 0.224 |
| Tumor size | 15.6 | 1.340 | 1.210–1.484 | < 0.001 | 1.038 | 0.921–1.171 | 0.539 |
PAL prolonged air leak, BMI body mass index, COPD chronic obstructive pulmonary diseases, FEV1 forced expiratory volume in one second, MVV maximal voluntary ventilation, PNI prognostic nutritional index, ASA American Society of Anesthesiologists, RATS robotic-assisted thoracic surgery, VATS video-assisted thoracic surgery, LN lymph node
Details of the predictive model to calculate the probability of PAL
| Risk factors | Coefficient | SE | OR (95% CI) | |
|---|---|---|---|---|
| Intercept | − 0.276 | 0.849 | 0.759 | 0.745 |
| Age | 0.024 | 0.007 | 1.024 (1.009–1.038) | 0.001 |
| BMI | − 0.125 | 0.024 | 0.883 (0.842–0.926) | < 0.001 |
| Smoking history | 0.002 | |||
| Non-smoker | Ref. | |||
| Smoker | 0.482 | 0.158 | 1.620 (1.188–2.208) | |
| FEV1% predicted | − 0.012 | 0.004 | 0.988 (0.980–0.996) | 0.004 |
| Surgical procedure | < 0.001 | |||
| Sublobectomy | Ref. | |||
| Lobectomy | 0.870 | 0.165 | 2.388 (1.730–3.296) | |
| Surgical range | 0.002 | |||
| Mono-lobe | Ref. | |||
| Multi-lobe | 0.596 | 0.188 | 1.814 (1.255–2.623) | |
| Operation side | 0.032 | |||
| Left-sided | Ref. | |||
| Right-sided | − 0.315 | 0.147 | 0.730 (0.547–0.972) | |
| Operation duration | 0.009 | 0.002 | 1.009 (1.005–1.012) | < 0.001 |
PAL prolonged air leak, BMI body mass index, FEV1 forced expiratory volume in one second, SE standard error, OR odds ratio, CI confidence interval. Probability of PAL could be calculated by using the following formula: ln (p/1 − p) = 0.024 × age – 0.125 × BMI + 0.482 × smoking history (non-smoker = 0; smoker = 1) – 0.012 × FEV1% predicted + 0.870 × surgical procedure (sublobectomy = 0; lobectomy = 1) + 0.596 × surgical range (mono-lobe = 0; multi-lobe = 1) – 0.315 × operation side (left = 0; right = 1) + 0.009 × operation duration – 0.276
Fig. 2A nomogram for prediction of PAL risk after minimally invasive pulmonary resection. Draw a vertical line from the corresponding axis of each variable to the points axis to acquire the point of this variable. Make a summation of the points for each variable to yield a total score, and the probability of PAL could be estimated by projecting the total score to the lower total point axis. BMI, body mass index; FEV1, forced expiratory volume in one second; PAL, prolonged air leak
Fig. 3ROC curves of the nomogram for predicting PAL in the training and validation cohorts. ROC, receiver operating characteristic; AUC, areas under the ROC curve; PAL, prolonged air leak
Fig. 4Calibration curves of the prediction nomogram in the training cohort (A) and validation cohort (B). The x-axis represents the nomogram-predicted probability, and the y-axis represents the actual probability of PAL. The black pointed line represents the ideal curve, the red solid line represents the apparent curve (non-correction), and the blue solid line represents the bias-correction curve by bootstrapping (B = 1000 repetitions). PAL, prolonged air leak
Risk categories of PAL in validation cohort
| Risk categories | Predicted PAL risk (%) | Number of patients in validation cohort (n) | Incidence of PAL ( | Observed frequency of PAL (%) |
|---|---|---|---|---|
| Low risk | < 10% | 225 | 15 | 6.7 |
| Intermediate risk | 10%-20% | 186 | 25 | 13.4 |
| High risk | >20% | 142 | 42 | 29.6 |
PAL prolonged air leak
Fig. 5Decision curve analysis for the PAL nomogram in the training and validation cohorts. The y-axis measures the net benefit, the black line represents the assumption of PAL-none-patients, the gray line represents the assumption of PAL-all-patients, the red line represents the training cohort, and the blue line represents the validation cohort. PAL, prolonged air leak